Trial Profile
Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 17 Aug 2023 Planned End Date changed from 1 Sep 2023 to 26 Jun 2024.
- 15 Dec 2021 Planned End Date changed from 16 Sep 2024 to 16 Sep 2025.
- 15 Dec 2021 Planned primary completion date changed from 16 Sep 2022 to 16 Sep 2023.